Published : Sept. 29, 2017 - 13:09
Hanmi Pharmaceutical has presented two drug candidates employing its proprietary Lapscovery platform technology at the European Association for the Study of Diabetes.
The two therapies in development are a triple agonist for non-alcoholic fatty liver disease and Parkinson’s, and a glucagon analog for treating congenital hyperinsulinism.
Both drugs employ Hanmi’s Lapscovery — short for Long Acting Protein and Peptide Discovery — which extends the life of a biologic drug within the body, extending its efficacy and potency.
Hanmi Pharmaceutical introduces its new drug candidates employing its Lapscovery technology at the EASD conference in Lisbon. (Hanmi Pharmaceutical)
Hanmi presented the animal testing results of the two drugs and their efficacy during this year’s EASD conference in Lisbon, Portugal earlier this month.
A triple agonist is a biologic agent that simultaneously activates glucagon, an energy metabolism booster, as well as GLP-1 and GIP, which aid insulin uptake and release.
A glucagon analog instigates glucose synthesis by acting as a glucagon inhibitor. It has shown an ability to elevate blood sugar levels, suggesting it can become a potential treatment for hyperinsulinism, Hanmi said.
Both drugs have been developed as drugs requiring a single injection per week, according to the Korean drugmaker. Looking ahead, it plans to continue expanding the application of its Lapscovery technology into new disease areas.
By Sohn Ji-young (
jys@heraldcorp.com)